Revenue

A patent-pending tubing anchor catcher is showing early promise, with reports of 100% production gains by tackling stubborn gas interference issues.

A2Z Cust2Mate reports a pivotal quarter with up to $5.2M in Q4 revenue, as the delivery of over 2,000 AI-powered smart carts begins to pay off.

With its lead CAR-T therapy, Descartes-08, in late-stage trials, Cartesian Therapeutics is set to update investors on its pioneering work in autoimmune disease.

A new initiative offers biotech firms free access to advanced epiproteomic analysis, aiming to accelerate the development of next-generation precision medicines.

With a soaring stock, $300M in new funding, and strong clinical data, Monte Rosa is set to showcase its novel disease-fighting drug platform.

A new high-grade discovery deep beneath a century-old mine could revive a legendary BC mining district and bolster Canada's critical mineral supply.

A new three-tube collection system from BD promises to improve accuracy, streamline lab work, and enhance patient safety by reducing sample contamination.

A new platform by Dr. Jess Ingrassellino launches to demystify music tech, empowering a new generation of electric string players and their teachers.

New 12- and 24-month data for Benitec Biopharma's BB-301 gene therapy offers renewed hope for patients with a rare, debilitating muscular dystrophy.

Anavex Life Sciences adds AMEOS Group CEO Dr. Axel Paeger to its board, a strategic move signaling a push into European markets for its CNS therapies.

C4 Therapeutics begins a crucial study for its oral protein degrader, cemsidomide, offering new hope for heavily treated multiple myeloma patients.

With a key drug in trials and a pipeline nearing the clinic, Foghorn Therapeutics brings in a seasoned financial leader to navigate its path to market.

Montreal firm's advanced titanium powder will fuel next-gen aerospace innovation, highlighting its role in a critical, high-growth global market.

An Israeli-Brazilian partnership aims to deploy novel gene technology to protect vital corn harvests in South America from devastating drought.

With revenue growth tied to shrinking margins, illumin's upcoming 2025 earnings report is a critical test of its strategy in a shifting ad tech world.

The biotech firm slashed a major acquisition hurdle in a deal with HealthCare Royalty, signaling strong confidence in its cancer drug ZYNLONTA's future.

Keurig's ubiquitous K-Cup pods are now recyclable in Ontario, marking a pivotal test for the province's new producer-funded waste system.

The pizza giant posts robust sales and expands market share, crediting its 'Hungry for MORE' strategy and rewarding investors with a major dividend boost.

Armed with $320M in new capital, Anteris will showcase its revolutionary biomimetic heart valve to top investors. Can it disrupt a market of giants?

AxyomCore unveils a powerful 4G/5G network extender at MWC, claiming superior coverage and capacity that could disrupt the enterprise connectivity market.